← Back to Clinical Trials
Recruiting NCT06066268

NCT06066268 miRNAs in Critical Limb Ischemia (miRNACLI)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06066268
Status Recruiting
Phase
Sponsor IRCCS Policlinico S. Donato
Condition Critical Limb Ischemia
Study Type OBSERVATIONAL
Enrollment 80 participants
Start Date 2016-05-31
Primary Completion 2026-05-31

Eligibility & Interventions

Sex All sexes
Min Age 40 Years
Max Age 85 Years
Study Type OBSERVATIONAL
Interventions
Critical limb ischemia: analysis of RNAsControls: analysis of RNAs

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 80 participants in total. It began in 2016-05-31 with a primary completion date of 2026-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

For the present study, 40 patients affected by critical limb ischemia of different severity will be enrolled: patients affected by critical limb ischemia undergoing subgenual femoropopliteal bypass; patients suffering from terminal ischemia causing gangrene and therefore undergoing major amputation of the lower limb. Biopsies from the first 20 enrolled patients will be used for miRNA profiling. The total of 40 biopsies obtained from all enrolled patients will instead be used for the validation of the miRNAs identified in the profiling. The results obtained will be compared with those obtained in 40 control patients affected by infrarenal abdominal aortic aneurysm (AAA) undergoing endovascular exclusion surgery (EVAR) of the AAA without any ischemia of the lower limbs. Also in this case the biopsies of the first 20 control patients enrolled will be used for miRNA profiling. The total of 40 biopsies obtained from all control patients will instead be used for the validation of the miRNAs identified in the profiling. A total of 80 patients (40 cases and 40 controls) will be enrolled.

Eligibility Criteria

Inclusion Criteria: Cases: * patients affected by CLI candidates for popliteal exploration surgery and/or subgenual femoropopliteal bypass. * Patients affected by CLI with irreversible ischemia and/or distal gangrene of the lower limb candidates for major amputation of the lower limb. Controls: • patients affected by infrarenal abdominal aortic aneurysm (AAA) undergoing endovascular exclusion surgery of the AAA (EVAR) who are free from CLI, affected and not affected by type 2 diabetes mellitus. Exclusion Criteria: * Pregnant women * Patients carriers of genetic diseases * Patients suffering from malignant neoplasia

Contact & Investigator

Central Contact

Fabio Dr Martelli

✉ fabio.martelli@grupposandonato.it

📞 +39 0226437762

Principal Investigator

Fabio Martelli

PRINCIPAL INVESTIGATOR

IRCCS Policlinico S. Donato

Frequently Asked Questions

Who can join the NCT06066268 clinical trial?

This trial is open to participants of all sexes, aged 40 Years or older, up to 85 Years, studying Critical Limb Ischemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06066268 currently recruiting?

Yes, NCT06066268 is actively recruiting participants. Contact the research team at fabio.martelli@grupposandonato.it for enrollment information.

Where is the NCT06066268 trial being conducted?

This trial is being conducted at San Donato Milanese, Italy.

Who is sponsoring the NCT06066268 clinical trial?

NCT06066268 is sponsored by IRCCS Policlinico S. Donato. The principal investigator is Fabio Martelli at IRCCS Policlinico S. Donato. The trial plans to enroll 80 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology